Medigene Receives Milestone Fee from Regeneron Prescribed drugs, Inc.

• Fee triggered by improvement milestone achieved by Regeneron’s collaborator in China, JW Therapeutics
• Progresses first scientific use of Medigene’s Finish-to-Finish Platform to generate probably best-in-class TCRs

Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Firm”, FSE: MDG1, Prime Commonplace), an oncology platform firm centered on the analysis and improvement of T cell receptor (TCR)-guided therapies for the remedy of most cancers, at present introduced a USD $1 million milestone cost from Regeneron Prescribed drugs, Inc. was triggered. Regeneron bought the MAGE-A4-TCR program as a part of its acquisition of 2seventy bio Inc.’s pre-clinical and scientific oncology and autoimmune cell remedy pipeline, which closed in April 2024. The cost was triggered by a improvement milestone for a trial in China led by JW Therapeutics (additionally a previous collaborator of 2seventy bio, Inc.) of Regeneron’s MAGE-A4 cell remedy, which accommodates a Medigene generated T cell receptor (TCR) concentrating on MAGE-A4.

“We’re excited that this program is shifting ahead, incorporating our TCR directed at MAGE-A4 into the clinic and probably offering the primary scientific validation of our distinctive TCR discovery and technology capabilities and our Finish-to-Finish Platform applied sciences,” stated Dr. Selwyn Ho, Chief Government Officer of Medigene. “We look ahead to the outcomes of this trial and stay dedicated to delivering best-in-class, differentiated T cell receptors to be used in a number of TCR-guided therapies for sufferers with stable tumors.”

This cost has been included within the present monetary steering offered by the Firm, and due to this fact affirmation of this milestone doesn’t change 2024 steering.

— finish of press launch —

About Medigene AG
Medigene AG MDG is an immuno-oncology platform firm devoted to growing T cell receptor (TCR)-guided therapies to successfully remove most cancers. Its Finish-to-Finish Platform generates optimum 3S (delicate, particular and protected) T cell receptors with distinctive and distinctive attributes that may be utilized in a number of therapeutic modalities, equivalent to off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010), TCR-natural killer cell (TCR-NK) therapies and T cell receptor engineered T cell (TCR-T) therapies (MDG1015). For extra data, please go to

This press launch accommodates forward-looking statements representing the opinion of Medigene as of the date of this launch. The precise outcomes achieved by Medigene might differ considerably from the forward-looking statements made herein. Medigene is just not certain to replace any of those forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark could also be owned or licensed in choose areas solely.

Medigene AG
Pamela Keck
Telephone: +49 89 2000 3333 01
E mail: [email protected]

In case you now not want to obtain any details about Medigene, please inform us by e-mail ([email protected]). We are going to then delete your deal with from our distribution listing.